CN107320730A - A kind of nano-medicament carrier material and preparation method thereof - Google Patents
A kind of nano-medicament carrier material and preparation method thereof Download PDFInfo
- Publication number
- CN107320730A CN107320730A CN201710645345.6A CN201710645345A CN107320730A CN 107320730 A CN107320730 A CN 107320730A CN 201710645345 A CN201710645345 A CN 201710645345A CN 107320730 A CN107320730 A CN 107320730A
- Authority
- CN
- China
- Prior art keywords
- parts
- nano
- carrier material
- medicament carrier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
The invention provides a kind of nano-medicament carrier material and preparation method thereof.Preparation method is as follows：（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring reaction 1 1.5 hours；（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear；（3）Add cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde, heating stirring；（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；（5）Suspension pH value is adjusted to neutrality, is centrifuged 35 minutes under the 3000r/min of rotating speed 2500, is discarded solvent, be drying to obtain.The nano-medicament carrier material of the present invention has higher water absorption rate, and hydrophily is good, and degradation rate is very fast, while having good sustained drug release effect.
Description
Technical field
The present invention relates to biomedical materials field, and in particular to a kind of nano-medicament carrier material and preparation method thereof.
Background technology
It is administered by traditional approach, most drug composition discharges quickly, causes the rapid rise of internal levels of drugs, reach
Reduced rapidly after to peak value.And for medicine, its effect is closely related with the concentration of drug in blood serum, violent fluctuation is past
Unacceptable side effect is produced in peak value toward causing, insufficient control then is caused because the concentration of drug in blood serum is too low
Therapeutic effect.In order to maintain internal necessary drug concentration, regular medicine taking or injection for several times on the one can only be used, even in medicament
Arranged on amount and administration time interval, internal blood concentration is still within fluctuation status.And controlled release drug delivery system
Come across in the 1970s, being one kind in drug delivery system, it can be such that medicine is discharged with a kind of predetermined speed, make
Drug concentration in blood or tissue is maintained in the range of effective therapeutic index in a long time, and extension medicine is in medicine-feeding part
Holdup time, improve bioavilability, reach the effect of slow-release controlled-release.Relative to traditional administering mode, medicine control is released
Place system, which has, can be reacted with regulating drug rate of release, reduction administration number of times, generation appropriateness, improve curative effect of medication, reduce medicine
Thing toxic side effect, the pain for mitigating patient's medication, so that it is important to add the security of drug therapy, high efficiency and reliability etc.
Meaning.
The content of the invention
The technical problem to be solved：It is an object of the invention to provide a kind of nano-medicament carrier material, with higher suction
Water rate, hydrophily is good, and degradation rate is very fast, while having good sustained drug release effect.
Technical scheme：A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：Hyaluronic acid 0.5-
1.5 parts, 1-2 parts of fibroin albumen, 1-3 parts of soybean protein isolate, 1-2 parts of PLA, 10-14 parts of cotton edible vegetable oil, cationic starch
0.5-1 parts, 1-2 parts of gurgeon stopper leaf-alcohol, 3-6 parts of carboxymethyl chitosan, 2-3 parts of hydroxypropyl methyl cellulose, polyoxyethylene sorbitol
1-3 parts of acid anhydride monostearate, 4-7 parts of polyethylene glycol, 2-4 parts of glutaraldehyde, 50-70 parts of deionized water.
It is further preferred that a kind of described nano-medicament carrier material, is prepared from by following component with parts by weight：Thoroughly
Bright 0.7-1.2 parts of matter acid, 1.2-1.8 parts of fibroin albumen, 1.5-2.5 parts of soybean protein isolate, 1.3-1.8 parts of PLA, cotton are clear
Oily 11-13 parts, 0.6-0.9 parts of cationic starch, 1.2-1.8 parts of gurgeon stopper leaf-alcohol, 4-5 parts of carboxymethyl chitosan, hydroxypropyl methyl
2.2-2.7 parts of cellulose, 1.5-2.5 parts of polyoxyethylene sorbitan monostearate, 5-6 parts of polyethylene glycol, glutaraldehyde 2.4-
3.4 parts, 55-65 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material comprises the following steps：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1-1.5 hours；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
5-10 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 40-50 DEG C is heated to and stirs 5-6 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3-5 minutes under rotating speed 2500-3000r/min, discards solvent, is dried
Produce.
It is preferred that, step（3）In be heated to 45 DEG C, mixing time is 5.5 hours.
It is preferred that, step（5）Middle rotating speed is 2800r/min, and centrifugation time is 4 minutes.
Beneficial effect：The average grain diameter of the nano-medicament carrier material of the present invention is in 63.5-65.3nm, with higher suction
Water rate, reaches as high as 44.6%, hydrophily is good, and degradation rate is very fast, and its degradation rate is reachable after being soaked 30 days in phosphate buffer
To 76.0%, drug release rate is only insoluble drug release in 59.8%, 20h in minimum only 22.1%, the 10h of drug release rate in 2h
Rate just reaches 80.6%, with good sustained drug release effect.
Embodiment
Embodiment 1
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：0.5 part of hyaluronic acid, fibroin albumen 1
Part, 1 part of soybean protein isolate, 1 part of PLA, 10 parts of cotton edible vegetable oil, 0.5 part of cationic starch, 1 part of gurgeon stopper leaf-alcohol, carboxymethyl shell
3 parts of glycan, 2 parts of hydroxypropyl methyl cellulose, 1 part of polyoxyethylene sorbitan monostearate, 4 parts of polyethylene glycol, glutaraldehyde 2
Part, 50 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1 hour；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
5 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 40 DEG C is heated to and stirs 5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3 minutes under rotating speed 2500r/min, is discarded solvent, be drying to obtain.
Embodiment 2
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：0.7 part of hyaluronic acid, fibroin albumen 1.2
Part, 1.5 parts of soybean protein isolate, 1.3 parts of PLA, 11 parts of cotton edible vegetable oil, 0.6 part of cationic starch, 1.2 parts of gurgeon stopper leaf-alcohol, carboxylic
4 parts of methyl chitosan, 2.2 parts of hydroxypropyl methyl cellulose, 1.5 parts of polyoxyethylene sorbitan monostearate, polyethylene glycol 5
Part, 2.4 parts of glutaraldehyde, 55 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1 hour；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
6 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 45 DEG C is heated to and stirs 5.5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3 minutes under rotating speed 2700r/min, is discarded solvent, be drying to obtain.
Embodiment 3
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：1 part of hyaluronic acid, fibroin albumen 1.5
Part, 2 parts of soybean protein isolate, 1.5 parts of PLA, 12 parts of cotton edible vegetable oil, 0.75 part of cationic starch, 1.5 parts of gurgeon stopper leaf-alcohol, carboxylic first
4.5 parts of base enclosure glycan, 2.5 parts of hydroxypropyl methyl cellulose, 2 parts of polyoxyethylene sorbitan monostearate, polyethylene glycol 5.5
Part, 3 parts of glutaraldehyde, 60 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1.25 hours；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
8 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 45 DEG C is heated to and stirs 5.5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 4 minutes under rotating speed 2800r/min, is discarded solvent, be drying to obtain.
Embodiment 4
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：1.2 parts of hyaluronic acid, fibroin albumen 1.8
Part, 2.5 parts of soybean protein isolate, 1.8 parts of PLA, 13 parts of cotton edible vegetable oil, 0.9 part of cationic starch, 1.8 parts of gurgeon stopper leaf-alcohol, carboxylic
5 parts of methyl chitosan, 2.7 parts of hydroxypropyl methyl cellulose, 2.5 parts of polyoxyethylene sorbitan monostearate, polyethylene glycol 6
Part, 3.4 parts of glutaraldehyde, 65 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1.5 hours；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
9 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 45 DEG C is heated to and stirs 5.5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 5 minutes under rotating speed 2900r/min, is discarded solvent, be drying to obtain.
Embodiment 5
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：1.5 parts of hyaluronic acid, fibroin albumen 2
Part, 3 parts of soybean protein isolate, 2 parts of PLA, 14 parts of cotton edible vegetable oil, 1 part of cationic starch, 2 parts of gurgeon stopper leaf-alcohol, carboxymethyl chitosan
6 parts of sugar, 3 parts of hydroxypropyl methyl cellulose, 3 parts of polyoxyethylene sorbitan monostearate, 7 parts of polyethylene glycol, glutaraldehyde 4
Part, 70 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1.5 hours；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
10 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 50 DEG C is heated to and stirs 6 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 5 minutes under rotating speed 3000r/min, is discarded solvent, be drying to obtain.
Comparative example 1
The present embodiment and the difference of embodiment 2 are not containing fibroin albumen and soybean protein isolate.Specifically：
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：0.7 part of hyaluronic acid, PLA 1.3
Part, 11 parts of cotton edible vegetable oil, 0.6 part of cationic starch, 1.2 parts of gurgeon stopper leaf-alcohol, 4 parts of carboxymethyl chitosan, hydroxypropyl methyl cellulose
2.2 parts, 1.5 parts of polyoxyethylene sorbitan monostearate, 5 parts of polyethylene glycol, 2.4 parts of glutaraldehyde, 55 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1 hour；
（2）Add hyaluronic acid, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear 6 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 45 DEG C is heated to and stirs 5.5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3 minutes under rotating speed 2700r/min, is discarded solvent, be drying to obtain.
Comparative example 2
The present embodiment and the difference of embodiment 2 are not containing cationic starch and hydroxypropyl methyl cellulose.Specifically：
A kind of nano-medicament carrier material, is prepared from by following component with parts by weight：0.7 part of hyaluronic acid, fibroin albumen 1.2
It is part, 1.5 parts of soybean protein isolate, 1.3 parts of PLA, 11 parts of cotton edible vegetable oil, 1.2 parts of gurgeon stopper leaf-alcohol, 4 parts of carboxymethyl chitosan, poly-
1.5 parts of oxygen ethene sorbitan monostearate, 5 parts of polyethylene glycol, 2.4 parts of glutaraldehyde, 55 parts of deionized water.
The preparation method of above-mentioned nano-medicament carrier material is：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1 hour；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
6 minutes；
（3）Glutaraldehyde is added, 45 DEG C is heated to and stirs 5.5 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3 minutes under rotating speed 2700r/min, is discarded solvent, be drying to obtain.
The partial properties index of the nano-medicament carrier material of the present invention see the table below, it will be seen that material of the present invention
Average grain diameter in 63.5-65.3nm, with higher water absorption rate, reach as high as 44.6%, hydrophily is good, degradation rate is very fast,
Its degradation rate can reach 76.0% after being soaked 30 days in phosphate buffer, and it is only 22.1%, 10h that drug release rate is minimum in 2h
Interior drug release rate be only in 59.8%, 20h drug release rate just reach 80.6%, with good sustained drug release effect.
The partial properties index of the nano-medicament carrier material of table 1
Claims (5)
1. a kind of nano-medicament carrier material, it is characterised in that：It is prepared from by following component with parts by weight：Hyaluronic acid 0.5-
1.5 parts, 1-2 parts of fibroin albumen, 1-3 parts of soybean protein isolate, 1-2 parts of PLA, 10-14 parts of cotton edible vegetable oil, cationic starch
0.5-1 parts, 1-2 parts of gurgeon stopper leaf-alcohol, 3-6 parts of carboxymethyl chitosan, 2-3 parts of hydroxypropyl methyl cellulose, polyoxyethylene sorbitol
1-3 parts of acid anhydride monostearate, 4-7 parts of polyethylene glycol, 2-4 parts of glutaraldehyde, 50-70 parts of deionized water.
2. a kind of nano-medicament carrier material according to claim 1, it is characterised in that：By following component with parts by weight system
It is standby to form：0.7-1.2 parts of hyaluronic acid, 1.2-1.8 parts of fibroin albumen, 1.5-2.5 parts of soybean protein isolate, PLA 1.3-
1.8 parts, 11-13 parts of cotton edible vegetable oil, 0.6-0.9 parts of cationic starch, 1.2-1.8 parts of gurgeon stopper leaf-alcohol, 4-5 parts of carboxymethyl chitosan,
2.2-2.7 parts of hydroxypropyl methyl cellulose, 1.5-2.5 parts of polyoxyethylene sorbitan monostearate, 5-6 parts of polyethylene glycol,
2.4-3.4 parts of glutaraldehyde, 55-65 parts of deionized water.
3. a kind of preparation method of nano-medicament carrier material described in any one of claim 1 to 2, it is characterised in that：Including
Following steps：
（1）Carboxymethyl chitosan, cotton edible vegetable oil, polyoxyethylene sorbitan monostearate and deionized water are mixed, stirring is anti-
Answer 1-1.5 hours；
（2）Add hyaluronic acid, fibroin albumen, soybean protein isolate, PLA, gurgeon stopper leaf-alcohol and polyethylene glycol, ultrasonic shear
5-10 minutes；
（3）Cationic starch, hydroxypropyl methyl cellulose and glutaraldehyde are added, 40-50 DEG C is heated to and stirs 5-6 hours；
（4）Aqueous phase is obtained after standing separation, regulation pH value to 8, low-speed centrifugal removes larger particle；
（5）Suspension pH value is adjusted to neutrality, is centrifuged 3-5 minutes under rotating speed 2500-3000r/min, discards solvent, is dried
Produce.
4. a kind of preparation method of nano-medicament carrier material according to claim 4, it is characterised in that：The step
（3）In be heated to 45 DEG C, mixing time is 5.5 hours.
5. a kind of preparation method of nano-medicament carrier material according to claim 4, it is characterised in that：The step
（5）Middle rotating speed is 2800r/min, and centrifugation time is 4 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710645345.6A CN107320730A (en) | 2017-08-01 | 2017-08-01 | A kind of nano-medicament carrier material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710645345.6A CN107320730A (en) | 2017-08-01 | 2017-08-01 | A kind of nano-medicament carrier material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107320730A true CN107320730A (en) | 2017-11-07 |
Family
ID=60225245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710645345.6A Withdrawn CN107320730A (en) | 2017-08-01 | 2017-08-01 | A kind of nano-medicament carrier material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107320730A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081708A1 (en) * | 2001-10-09 | 2004-04-29 | Baxter Jeffrey H. | Methods and compositions for providing glutamine |
| CN101455645A (en) * | 2008-12-30 | 2009-06-17 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of medicine microspheres using plant soy protein as carrier |
| CN106727441A (en) * | 2016-12-29 | 2017-05-31 | 厦门金达威生物科技有限公司 | Water-soluble nano slow-release function Co-Q10 microcapsules and preparation method and application |
-
2017
- 2017-08-01 CN CN201710645345.6A patent/CN107320730A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081708A1 (en) * | 2001-10-09 | 2004-04-29 | Baxter Jeffrey H. | Methods and compositions for providing glutamine |
| CN101455645A (en) * | 2008-12-30 | 2009-06-17 | 上海纳米技术及应用国家工程研究中心有限公司 | Preparation method of medicine microspheres using plant soy protein as carrier |
| CN106727441A (en) * | 2016-12-29 | 2017-05-31 | 厦门金达威生物科技有限公司 | Water-soluble nano slow-release function Co-Q10 microcapsules and preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 刘妙丽，等: "《纺织化学》", 31 August 2007, 中国纺织出版社 * |
| 顾其胜，等: "《实用生物医用材料学》", 30 September 2005, 上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU500813B1 (en) | Asiaticoside-chitosan-sodium Alginate Microsphere and Preparation Method and Application thereof | |
| KR20030051687A (en) | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight | |
| CN106038478B (en) | A kind of porous microsphere of glucose-sensitive/polymer plural gel and its preparation method and application | |
| JPS63253030A (en) | Slow release composition | |
| CN106420668B (en) | A kind of starch base control slow releasing carrier material and the preparation method and application thereof | |
| US20220088276A1 (en) | Sustained-release injection formulation comprising conjugate of poly-l-lactic acid filler and hyaluronic acid filler and bioactive materials, and preparation method thereof | |
| CN104840428B (en) | A kind of hyaluronic acid-chitosan microballoon for being loaded with epidermal growth factor and its preparation method and application | |
| JP5080474B2 (en) | PH-sensitive nanoparticle formulations for oral protein / peptide delivery | |
| CN1903207A (en) | Fat-soluble vitamin freeze-dried prepn. and its prepn. method | |
| CN106924750A (en) | A kind of Suo Malu peptides oral microparticles preparation and preparation method thereof | |
| CN109172537B (en) | Preparation method of fish oil soft capsules | |
| WO2021101139A1 (en) | Injection formulation containing poly-l-lactic acid filler and hyaluronic acid filler conjugate, and method for preparing same | |
| CN113209028A (en) | Insulin-loaded glucose-sensitive phenylboronic acid group epsilon-polylysine particles and preparation method thereof | |
| CN107320730A (en) | A kind of nano-medicament carrier material and preparation method thereof | |
| CN114632145B (en) | Insulin-loaded phenylboronic acid/fatty acid double-modified epsilon-polylysine particles and preparation method thereof | |
| CN116327740A (en) | Lactoferrin patch and application thereof in preparation of medicines for treating recurrent respiratory tract infection of children | |
| CN110314151B (en) | Medical mesoporous silica material and application thereof | |
| CN1193761C (en) | Controllable release system of glucocorticoid and its preparation and use | |
| CN108159428A (en) | A kind of Thermosensitive Material Used for Controlled Releasing of Medicine and preparation method thereof | |
| CN107320729A (en) | A kind of combination drug carrier material and preparation method thereof | |
| Baranes‐Zeevi et al. | Novel drug‐eluting soy‐protein structures for wound healing applications | |
| CN109157529B (en) | Preparation method of enoxaparin sodium microspheres | |
| CN106109400A (en) | A kind of oral drugs hydrogel slow-released carrier and preparation method and applications | |
| CN109432043A (en) | Medical mulberry protein adhesive softgel shell and preparation method thereof | |
| CN107375244A (en) | A kind of nanoscale docetaxel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171107 |
|
| WW01 | Invention patent application withdrawn after publication |